Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Licking latency with licorice.

Jeffrey I Cohen1

  • 1Medical Virology Section, Laboratory of Clinical Infectious Diseases, NIH, Bethesda, Maryland 20892, USA. jcohen@niaid.nih.gov

The Journal of Clinical Investigation
|March 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transgene Expression Kinetics and Replication Potential of Recombinant Adenovirus Serotype 4 in a Mouse Model and its Use as a Herpes Simplex Virus Vaccine.

bioRxiv : the preprint server for biology·2026
Same author

Immunization with Herpes Simplex Virus Nanoparticles Targeting Both Attachment and Fusion Protect Against Infection.

bioRxiv : the preprint server for biology·2026
Same author

Intranasal Replicating Adenovirus type 4-SARS-CoV-2 Recombinants Induce Superior Immune Response Durability and Efficacy in Preclinical Testing Compared to Standard Intramuscular Vaccines.

bioRxiv : the preprint server for biology·2026
Same author

Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.

iScience·2026
Same author

Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.

medRxiv : the preprint server for health sciences·2026
Same author

Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.

The Journal of allergy and clinical immunology·2026
Same journal

Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adults.

The Journal of clinical investigation·2026
Same journal

Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

The Journal of clinical investigation·2026
Same journal

Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer.

The Journal of clinical investigation·2026
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
See all related articles

Glycyrrhizic acid, from licorice, shows promise in treating latent Kaposi sarcoma-associated herpesvirus (KSHV) infections. This compound reduced viral protein synthesis and induced cell death in infected cells, offering a new approach to interrupt viral latency.

Area of Science:

  • Virology
  • Molecular Biology
  • Immunology

Background:

  • Many viruses establish latent infections in humans, leading to chronic illness and suffering.
  • Current treatments focus on managing active infections or preventing reactivation, but eradicating latent viruses remains a challenge.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is a significant cause of latent infection with limited therapeutic options for eradication.

Discussion:

  • This study investigates the potential of glycyrrhizic acid, a natural compound from licorice, as a therapeutic agent against latent KSHV infection.
  • Glycyrrhizic acid demonstrated the ability to decrease the synthesis of a key viral latency protein.
  • The treatment also effectively induced apoptosis (programmed cell death) in KSHV-infected cells.

Key Insights:

Related Experiment Videos

  • Glycyrrhizic acid disrupts the maintenance of KSHV latency by inhibiting viral protein production.
  • The compound triggers the elimination of latently infected cells, suggesting a direct antiviral effect.
  • This research identifies a novel therapeutic strategy targeting latent viral reservoirs.

Outlook:

  • Further research is needed to explore the efficacy and safety of glycyrrhizic acid in preclinical and clinical settings.
  • This approach could potentially be extended to other human herpesviruses that establish latent infections.
  • Developing therapies to eradicate latent viral infections is crucial for improving patient outcomes and reducing disease burden.